Related Experiment Video
Updated: May 17, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Recent advances in drug eluting stents
Amey S Puranik1, Eileen R Dawson, Nicholas A Peppas
1Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
International Journal of Pharmaceutics
|November 3, 2012
Summary
Drug-eluting stents (DES) treat blocked arteries but can cause restenosis. Research focuses on biodegradable stents and advanced drug delivery to improve safety and efficacy, preventing re-narrowing.
Area of Science:
- Biomedical Engineering
- Cardiovascular Medicine
- Materials Science
Background:
- Coronary stents are vital for reopening occluded vessels.
- Restenosis, caused by smooth muscle cell hyperplasia, is a common complication.
- First-generation drug-eluting stents (DES) showed long-term safety concerns.
Purpose of the Study:
- To review the current state of drug-eluting stent technology.
- To identify challenges and limitations associated with existing DES.
- To highlight ongoing research in advanced stent development.
Main Methods:
- Literature review of drug-eluting stent technology.
- Analysis of mechanisms behind restenosis and neointimal hyperplasia.
- Examination of advancements in biodegradable stents and drug delivery systems.
Main Results:
- DES offer controlled drug release to inhibit neointima formation.
- Limitations in safety and efficacy of current DES necessitate further innovation.
- Biodegradable stents and improved drug delivery systems are key research areas.
Conclusions:
- Drug-eluting stents are crucial but face challenges like restenosis and long-term safety.
- Ongoing research aims to develop safer, more effective biodegradable stents.
- Advanced drug delivery systems are essential for preventing hyperplasia and improving patient outcomes.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...